Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Identification of De Novo Enhancers Activated by TGFβ to Drive Expression of CDKN2A and B in HeLa Cells.

Liu YT, Xu L, Bennett L, Hooks JC, Liu J, Zhou Q, Liem P, Zheng Y, Skapek SX.

Mol Cancer Res. 2019 Jun 12. doi: 10.1158/1541-7786.MCR-19-0289. [Epub ahead of print]

PMID:
31189690
2.

Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding.

Li S, Chen K, Zhang Y, Barnes SD, Jaichander P, Zheng Y, Hassan M, Malladi VS, Skapek SX, Xu L, Bassel-Duby R, Olson EN, Liu N.

Genes Dev. 2019 Jun 1;33(11-12):626-640. doi: 10.1101/gad.324467.119. Epub 2019 Apr 11.

PMID:
30975722
3.

Rhabdomyosarcoma.

Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS.

Nat Rev Dis Primers. 2019 Jan 7;5(1):1. doi: 10.1038/s41572-018-0051-2. Review.

PMID:
30617281
4.

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH.

J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9.

5.

Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.

Xu L, Zheng Y, Liu J, Rakheja D, Singleterry S, Laetsch TW, Shern JF, Khan J, Triche TJ, Hawkins DS, Amatruda JF, Skapek SX.

Cell Rep. 2018 Jul 3;24(1):238-251. doi: 10.1016/j.celrep.2018.06.006.

6.

PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis.

Kendall GC, Watson S, Xu L, LaVigne CA, Murchison W, Rakheja D, Skapek SX, Tirode F, Delattre O, Amatruda JF.

Elife. 2018 Jun 5;7. pii: e33800. doi: 10.7554/eLife.33800.

7.

Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group.

Laetsch TW, Roy A, Xu L, Black JO, Coffin CM, Chi YY, Tian J, Spunt SL, Hawkins DS, Bridge JA, Parsons DW, Skapek SX.

Clin Cancer Res. 2018 Aug 15;24(16):3888-3897. doi: 10.1158/1078-0432.CCR-18-0672. Epub 2018 Apr 24.

8.

Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.

Teot LA, Schneider M, Thorner AR, Tian J, Chi YY, Ducar M, Lin L, Wlodarski M, Grier HE, Fletcher CDM, van Hummelen P, Skapek SX, Hawkins DS, Wagers AJ, Rodriguez-Galindo C, Hettmer S.

Cancer. 2018 May 1;124(9):1973-1981. doi: 10.1002/cncr.31286. Epub 2018 Feb 20.

9.

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26645. Epub 2017 May 18.

10.

Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group.

Xu L, Wilson RA, Laetsch TW, Oliver D, Spunt SL, Hawkins DS, Skapek SX.

Sci Rep. 2016 Sep 19;6:33429. doi: 10.1038/srep33429.

11.

The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Sankaran H, Danysh HE, Scheurer ME, Okcu MF, Skapek SX, Hawkins DS, Spector LG, Erhardt EB, Grufferman S, Lupo PJ.

Pediatr Blood Cancer. 2016 Sep;63(9):1557-62. doi: 10.1002/pbc.26065. Epub 2016 May 19.

12.

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR.

Cancer Genet. 2016 May;209(5):182-94. doi: 10.1016/j.cancergen.2016.03.004. Epub 2016 Apr 5. Review.

13.

Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases.

Wilson RA, Liu J, Xu L, Annis J, Helmig S, Moore G, Timmerman C, Grandori C, Zheng Y, Skapek SX.

Sci Rep. 2016 Feb 5;6:20376. doi: 10.1038/srep20376.

14.

p19(Arf) limits primary vitreous cell proliferation driven by PDGF-B.

Iqbal NS, Devitt CC, Sung CY, Skapek SX.

Exp Eye Res. 2016 Apr;145:224-229. doi: 10.1016/j.exer.2016.01.004. Epub 2016 Jan 8.

15.

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.

Arnold MA, Anderson JR, Gastier-Foster JM, Barr FG, Skapek SX, Hawkins DS, Raney RB Jr, Parham DM, Teot LA, Rudzinski ER, Walterhouse DO.

Pediatr Blood Cancer. 2016 Apr;63(4):634-9. doi: 10.1002/pbc.25862. Epub 2016 Jan 12.

16.

Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.

Roy A, Kumar V, Zorman B, Fang E, Haines KM, Doddapaneni H, Hampton OA, White S, Bavle AA, Patel NR, Eldin KW, John Hicks M, Rakheja D, Leavey PJ, Skapek SX, Amatruda JF, Nuchtern JG, Chintagumpala MM, Wheeler DA, Plon SE, Sumazin P, Parsons DW.

Nat Commun. 2015 Nov 17;6:8891. doi: 10.1038/ncomms9891.

17.

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Hingorani P, Missiaglia E, Shipley J, Anderson JR, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, Skapek SX.

Clin Cancer Res. 2015 Oct 15;21(20):4733-9. doi: 10.1158/1078-0432.CCR-14-3326.

18.

The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Rudzinski ER, Anderson JR, Hawkins DS, Skapek SX, Parham DM, Teot LA.

Arch Pathol Lab Med. 2015 Oct;139(10):1281-7. doi: 10.5858/arpa.2014-0475-OA. Epub 2015 May 19.

19.

Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database.

Lupo PJ, Danysh HE, Plon SE, Curtin K, Malkin D, Hettmer S, Hawkins DS, Skapek SX, Spector LG, Papworth K, Melin B, Erhardt EB, Grufferman S, Schiffman JD.

Cancer Med. 2015 May;4(5):781-90. doi: 10.1002/cam4.448. Epub 2015 Mar 23.

20.

Clonality and evolutionary history of rhabdomyosarcoma.

Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, Khan J.

PLoS Genet. 2015 Mar 13;11(3):e1005075. doi: 10.1371/journal.pgen.1005075. eCollection 2015 Mar.

21.

Sarcomas.

HaDuong JH, Martin AA, Skapek SX, Mascarenhas L.

Pediatr Clin North Am. 2015 Feb;62(1):179-200. doi: 10.1016/j.pcl.2014.09.012. Review.

PMID:
25435119
22.

Odontogenic myxoma of the face: mimicry of cherubism.

Kleiber GM, Skapek SX, Lingen M, Reid RR.

J Oral Maxillofac Surg. 2014 Nov;72(11):2186-91. doi: 10.1016/j.joms.2014.05.027. Epub 2014 Jun 2.

PMID:
25200927
23.

Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group.

Lupo PJ, Danysh HE, Skapek SX, Hawkins DS, Spector LG, Zhou R, Okcu MF, Papworth K, Erhardt EB, Grufferman S.

Cancer Causes Control. 2014 Jul;25(7):905-13. doi: 10.1007/s10552-014-0390-6. Epub 2014 May 16.

24.

Isolation and characterization of mammalian cells expressing the Arf promoter during eye development.

Iqbal NS, Xu L, Devitt CC, Skapek SX.

Biotechniques. 2014 May 1;56(5):239-49. doi: 10.2144/000114166. eCollection 2014 May.

25.

Varied manifestations of persistent hyperplastic primary vitreous with graded somatic mosaic deletion of a single gene.

Mary-Sinclair MN, Wang X, Swanson DJ, Sung CY, Mendonca EA, Wroblewski K, Baumer SH, Goldowitz D, Jablonski MM, Skapek SX.

Mol Vis. 2014 Mar 3;20:215-30. eCollection 2014.

26.

Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM.

Am J Surg Pathol. 2014 May;38(5):654-9. doi: 10.1097/PAS.0000000000000195.

27.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.

Cancer Discov. 2014 Feb;4(2):216-31. doi: 10.1158/2159-8290.CD-13-0639. Epub 2014 Jan 23.

28.

miR-34a is essential for p19(Arf)-driven cell cycle arrest.

Iqbal N, Mei J, Liu J, Skapek SX.

Cell Cycle. 2014;13(5):792-800. doi: 10.4161/cc.27725. Epub 2014 Jan 8.

29.

Arf induction by Tgfβ is influenced by Sp1 and C/ebpβ in opposing directions.

Zheng Y, Devitt C, Liu J, Iqbal N, Skapek SX.

PLoS One. 2013 Aug 5;8(8):e70371. doi: 10.1371/journal.pone.0070371. Print 2013.

30.

A novel algorithm for simplification of complex gene classifiers in cancer.

Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS, Anderson JR, Skapek SX, Volchenboum SL.

Cancer Res. 2013 Sep 15;73(18):5625-32. doi: 10.1158/0008-5472.CAN-13-0324. Epub 2013 Aug 2.

31.

Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group.

Lupo PJ, Zhou R, Skapek SX, Hawkins DS, Spector LG, Scheurer ME, Fatih Okcu M, Melin B, Papworth K, Erhardt EB, Grufferman S.

Int J Cancer. 2014 Jan 15;134(2):431-6. doi: 10.1002/ijc.28363. Epub 2013 Aug 1.

32.

Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM.

Am J Clin Pathol. 2013 Jul;140(1):82-90. doi: 10.1309/AJCPA1WN7ARPCMKQ.

33.

A distant, cis-acting enhancer drives induction of Arf by Tgfβ in the developing eye.

Zheng Y, Devitt C, Liu J, Mei J, Skapek SX.

Dev Biol. 2013 Aug 1;380(1):49-57. doi: 10.1016/j.ydbio.2013.05.003. Epub 2013 May 9.

34.

Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.

Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD.

FASEB J. 2013 Aug;27(8):2946-56. doi: 10.1096/fj.12-218040. Epub 2013 Apr 19. Erratum in: FASEB J. 2014 Jan;28(1):520. FASEB J. 2014 Jan;28(1):520.

35.

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS.

Pediatr Blood Cancer. 2013 Sep;60(9):1411-7. doi: 10.1002/pbc.24532. Epub 2013 Mar 22.

36.

Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.

Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, Kao S, Hoffer FA, Grier HE, Hawkins DS, Raney RB.

Pediatr Blood Cancer. 2013 Jul;60(7):1108-12. doi: 10.1002/pbc.24457. Epub 2012 Dec 31.

37.

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Hawkins DS, Spunt SL, Skapek SX; COG Soft Tissue Sarcoma Committee.

Pediatr Blood Cancer. 2013 Jun;60(6):1001-8. doi: 10.1002/pbc.24435. Epub 2012 Dec 19. Review.

38.

p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms.

Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, Skapek SX.

Mol Cell Biol. 2012 Nov;32(21):4270-82. doi: 10.1128/MCB.06424-11. Epub 2012 Aug 20.

39.

The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Rosenberg AR, Skapek SX, Hawkins DS.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1012-8. doi: 10.1158/1055-9965.EPI-12-0207. Epub 2012 May 7. Review.

40.

Temporally distinct roles for tumor suppressor pathways in cell cycle arrest and cellular senescence in Cyclin D1-driven tumor.

Zalzali H, Harajly M, Abdul-Latif L, El-Chaar N, Dbaibo G, Skapek SX, Saab R.

Mol Cancer. 2012 May 1;11:28. doi: 10.1186/1476-4598-11-28.

41.

Desmoid-type fibromatosis in children: a step forward in the cooperative group setting.

Pounds N, Skapek SX.

Am Soc Clin Oncol Educ Book. 2012:593-7. doi: 10.14694/EdBook_AM.2012.32.593.

PMID:
24451802
42.

The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Spunt SL, Vargas SO, Coffin CM, Skapek SX, Parham DM, Darling J, Hawkins DS, Keller C.

Cancer. 2012 Jun 15;118(12):3002-9. doi: 10.1002/cncr.26620. Epub 2011 Oct 17. No abstract available.

43.

Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.

Al-Tahan A, Sarkis O, Harajly M, Baghdadi OK, Zibara K, Boulos F, Dighe D, Kregel S, Bazarbachi A, El-Sabban M, Skapek SX, Saab R.

Pediatr Blood Cancer. 2012 Jun;58(6):877-84. doi: 10.1002/pbc.23246. Epub 2011 Jul 13.

PMID:
21755593
44.

Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.

Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS.

J Clin Oncol. 2011 Apr 1;29(10):1304-11. doi: 10.1200/JCO.2010.29.4611. Epub 2011 Feb 28.

45.

Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle.

Saab R, Spunt SL, Skapek SX.

Curr Top Dev Biol. 2011;94:197-234. doi: 10.1016/B978-0-12-380916-2.00007-3. Review.

PMID:
21295688
46.

Tgfbeta signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK.

Zheng Y, Zhao YD, Gibbons M, Abramova T, Chu PY, Ash JD, Cunningham JM, Skapek SX.

J Biol Chem. 2010 Nov 12;285(46):35654-64. doi: 10.1074/jbc.M110.128959. Epub 2010 Sep 8.

47.

Childhood rhabdomyosarcoma: new insight on biology and treatment.

Huh WW, Skapek SX.

Curr Oncol Rep. 2010 Nov;12(6):402-10. doi: 10.1007/s11912-010-0130-3. Review.

PMID:
20820958
48.

Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ.

J Clin Oncol. 2010 Oct 10;28(29):e587-8; author reply e589-90. doi: 10.1200/JCO.2010.30.5466. Epub 2010 Aug 9. No abstract available.

PMID:
20697086
49.

Expression of the Arf tumor suppressor gene is controlled by Tgfbeta2 during development.

Freeman-Anderson NE, Zheng Y, McCalla-Martin AC, Treanor LM, Zhao YD, Garfin PM, He TC, Mary MN, Thornton JD, Anderson C, Gibbons M, Saab R, Baumer SH, Cunningham JM, Skapek SX.

Development. 2009 Jun;136(12):2081-9. doi: 10.1242/dev.033548.

50.

p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Saab R, Rodriguez-Galindo C, Matmati K, Rehg JE, Baumer SH, Khoury JD, Billups C, Neale G, Helton KJ, Skapek SX.

Cancer Res. 2009 Jan 15;69(2):440-8. doi: 10.1158/0008-5472.CAN-08-1892.

Supplemental Content

Loading ...
Support Center